Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24076052 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Sebastian Korste und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, 45147 Essen, Germany. Hauptthemen laut MEDLINE: Anthracyclines, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Universitätsmedizin Essen Clinician Scientist Academy (UMEA)/German Research Foundation (DFG, Deutsche Forschungsgemeinschaft).
Abstract (Originalsprache)
Cancer survival rates have increased significantly because of improvements in therapy regimes and novel immunomodulatory drugs. Recently, combination therapies of anthracyclines and immune checkpoint inhibitors (ICIs) have been proposed to maximize neoplastic cell removal. However, it has been speculated that a priori anthracycline exposure may prone the heart vulnerable to increased toxicity from subsequent ICI therapy, such as an anti-programmed cell death protein 1 (PD1) inhibitor. Here, we used a high-dose anthracycline mouse model to characterize the role of the PD1 immune checkpoint signaling pathway in cardiac tissue using flow cytometry and immunostaining. Anthracycline treatment led to decreased heart function, increased concentration of markers of cell death after six days and a change in heart cell population composition with fewer cardiomyocytes. At the same time point, the number of PD1 ligand (PDL1)-positive immune cells and endothelial cells in the heart decreased significantly. The results suggest that PD1/PDL1 signaling is affected after anthracycline treatment, which may contribute to an increased susceptibility to immune-related adverse events of subsequent anti-PD1/PDL1 cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen, 45147 Essen, Germany.
- Deutsches Herzzentrum der Charité, Department of Cardiology, Angiology and Intensive Care Medicine, 12203 Berlin, Germany.
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, 10117 Berlin, Germany.
- Berlin Institute of Health Center for Regenerative Therapies (BCRT), 13353 Berlin, Germany.
- German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, 10785 Berlin, Germany.
- Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V., 44139 Dortmund, Germany.
ORCID-Profile: Sebastian Korste, Tienush Rassaf
Förderung
- Deutsche Forschungsgemeinschaft
- Universitätsmedizin Essen Clinician Scientist Academy (UMEA)/German Research Foundation (DFG, Deutsche Forschungsgemeinschaft)
Zitieren
APA
Korste, S., Settelmeier, S., Michel, L., Odersky, A., Stock, P., Reyes, F., Haj-Yehia, E., Anker, M. S., Grüneboom, A., Hendgen-Cotta, U. B., Rassaf, T., & Totzeck, M. (2023). Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076052
Vancouver
Korste S, Settelmeier S, Michel L, Odersky A, Stock P, Reyes F, et al. Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076052
BibTeX
@article{Korste2023,
author = {Korste, Sebastian and Settelmeier, Stephan and Michel, Lars and Odersky, Andrea and Stock, Pia and Reyes, Fabrice and Haj-Yehia, Elias and Anker, Markus S and Grüneboom, Anika and Hendgen-Cotta, Ulrike B and Rassaf, Tienush and Totzeck, Matthias},
title = {Anthracycline Therapy Modifies Immune Checkpoint Signaling in the Heart},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24076052}
}
EUVIMED